Edmonton, Alberta, January 2, 2025 – Innovotech Inc. (TSX-V: IOT) (“Innovotech” or the “Company”) is pleased to report that its invention for the use of antimicrobial silver compounds, including InnovoSIL™-1 silver, in a variety of formulations, was issued as European Patent No. 3 804 521 on January 1, 2025.
The patent includes claims for medical devices with Innovotech’s active silver compounds coated onto or incorporated into them, focusing on inclusion of the InnovoSIL™-1 silver into a polymer or hydrogel surface layer or layers. The applications include catheters, cannulae, needles, stents, guide wires, implant devices, filters, surgical or medical instruments, endotracheal tubes, gastroenteric feeding tubes, shunts, condoms, oxygenator and kidney membranes, gloves, pacemaker leads, wound dressings or gels, pins, plates, screws, artificial joints, and more.
InnovoSIL™-1 silver, as well as related compounds covered by this patent, has broad spectrum activity against bacterial and fungal biofilms associated with human, animal, and plant infections. InnovoSIL™-1 silver also effective against viruses and spores, and provides a potential solution to the growing challenges associated with antibiotic resistance, due to multiple unique mechanisms of action.
The issue of this patent allows Innovotech to licence these applications of antimicrobial silvers to industry partners in Europe interested in enhancing the antiplanktonic, antiviral, anti-adherence, or antibiofilm properties of their products.
